{"id":"W3163069657","doi":"10.1016/j.ygyno.2020.05.233","title":"GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Taxane; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399851,0.001651701,0.001947479,0.0005302226,0.0004792673,0.001094421,0.001116617,0.001828279,0.01078765],"category_scores_gemma":[0.001037651,0.0004872062,0.00130249,0.0004578721,0.001157061,0.001255907,0.0004725108,0.004320627,0.001671748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001099668,"about_ca_system_score_gemma":0.001563773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001519382,"about_ca_topic_score_gemma":0.00643281,"domain_scores_codex":[0.9996241,0.0001775622,0.00001201261,0.00007533046,0.00002649012,0.00008451477],"domain_scores_gemma":[0.9994862,0.0001123161,0.00008417665,0.0000345934,0.00002200736,0.0002607249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9044956,0.0180513,0.001079592,0.0009958559,0.0007839963,0.00006891433,0.0001060541,0.001330173,0.006467239,0.0007184745,0.006230813,0.05967198],"study_design_scores_gemma":[0.9311867,0.06405026,0.001334144,0.00003840071,0.0002053574,0.00005364455,0.0000336329,0.0006837524,0.0004661524,0.0003334093,0.001598208,0.00001644241],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679732,0.004457904,0.001530937,0.002528043,0.0009433284,0.007678292,0.00587461,0.000654697,0.008358898],"genre_scores_gemma":[0.9659612,0.002878174,0.003959411,0.003293186,0.0003708353,0.007745684,0.005190124,0.0001062192,0.01049524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01078765,"threshold_uncertainty_score":0.03608823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2867256213653118,"score_gpt":0.4777661927906862,"score_spread":0.1910405714253744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}